Ad Scientiam announces the clinical validation of its MSCopilot® solution

MSCopilot®, Ad Scientiam's solution for monitoring patients with multiple sclerosis, has been clinically compared with the standard tests of the Multiple Sclerosis Functional Composite (MSFC).

These results crown a 4-year R&D effort: MSCopilot® is now a CE-marked Class I software medical device dedicated to monitoring patients with multiple sclerosis. It was developed in collaboration with physicians and patients and received institutional support from Roche France.